News
-
-
-
PRESS RELEASE
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
NanoViricides, Inc. announces promising results for drug NV-387 against Measles virus, showing dual benefits in cell culture and animal models. NV-387 also demonstrates safety and unique mechanism of action -
-
-
PRESS RELEASE
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
NanoViricides, Inc. announces NV-387, a drug showing strong activity against Measles virus in an animal model, available for emergency use. Drug has completed Phase I clinical trial -
-
-
PRESS RELEASE
NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
NanoViricides, Inc. reveals dual-track clinical development strategy for NV-387 targeting respiratory viral infections including Influenzas, Coronaviruses, RSV. Analyst report details trials and future prospects -
